$GGB

Da Cunha Gustavo Werneck purchased $782K of GGB

Da Cunha Gustavo Werneck (CEO and Board Member) purchased 165,224 shares of GERDAU S.A. (GGB) at $4.73 ($0.78M total) on 2026-06-12.

Original reporting
SEC EDGAR · Da Cunha Gustavo Werneck
Published Jun 15, 2026, 8:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GGB
Bullish
medium confidence
Mentioned
$GGB
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GGBBullishLow
01

Why it matters

Traders may treat the filing as a small sentiment input, but it does not introduce new operational or financial information that would typically drive repricing.

02

Market read

A top insider bought shares at a stated price; useful for sentiment checks but unlikely to be a standalone catalyst.

03

What to watch

The article states the buy was not under a pre-arranged 10b5-1 plan, but it also shows the post-transaction holdings equal the purchased shares, which may reflect prior low/zero holdings rather than a strong conviction signal.

Relevance 6/10Novelty 6/10Timing: Filed 2026-06-15; transaction dated 2026-06-12

Background

The article is an SEC Form 4 insider transaction disclosure (open-market purchase) for Gerdau S.A. (GGB).

Company-level read

Ticker impact

$GGBBullishMedium confidence
Context

SEC Form 4 shows Gerdau CEO/board member Da Cunha Gustavo Werneck bought 165,224 shares open-market at $4.73 on 2026-06-12.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than a re-rating catalyst.

Evidence & confidence

The filing is primary-source and the buyer is a top insider, but the article provides no new company fundamentals (earnings, guidance, deals, or regulatory actions).

Market effects

No sector-wide read-across; this is a single-company insider transaction.

None indicated; the disclosure is company-specific.

None indicated; no cross-border deal/regulatory event described.

Counterpoint

Insider buys can be driven by diversification, liquidity needs, or pre-planned behavior; without 10b5-1 context, signal strength is limited.

Key entities

  • GERDAU S.A.

    Company whose shares were purchased by an insider; subject of the SEC Form 4 disclosure.

  • Da Cunha Gustavo Werneck

    CEO and board member who executed the open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GGBMed

Gerdau (GGB) Q3 2026 Earnings Call Transcript

Gerdau S.A. reported Q3 2026 earnings, highlighting BRL 1.7B free cash flow, BRL 0.34/share dividends, and a solid balance sheet. The company expects to return over BRL 1.85B to shareholders in 2026. North American operations showed strong demand, while Brazil faced seasonal slowdowns and import challenges. The company plans adjustments to improve Brazilian profitability and is awaiting government support on trade and energy policies.

$GGBMed

What Gerdau (GGB) Said on Its Q3 Earnings Call

Gerdau (GGB) is expanding capacity at its Texas facility, with full production expected by 2027. The company focuses on organic investments, not spin-offs or major acquisitions. Management discussed potential trade impacts on regional margins. In Brazil, Gerdau faces import pressure but plans productivity improvements. The company announced dividends and reduced capital expenditure plans to BRL 4 billion. Net debt to EBITDA is 0.58 times, with a positive outlook from S&P.

$GGBMedAI 8/10

Gerdau ADR earnings missed, revenue topped estimates

Gerdau ADR (GGB) reported Q3 EPS of $0.159, missing estimates of $0.165, while revenue of $3.75B exceeded expectations. The stock is down 4.23% over 3 months but up 37.28% year-over-year. Analysts revised EPS positively twice in the last 90 days. InvestingPro rates its financial health as good.